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Background and Aims: To assess the risk factors for sensory nerve dysfunction in subjects 
with isolated impaired glucose tolerance (IGT).  
Methods and Results: Seventy-two people with isolated IGT (WHO 1999 criteria) and 39 
gender and age-matched healthy volunteers underwent detailed clinical and neurological 
assessment including quantitative sensory testing using the Neurometer device (current 
perception threshold measurement on four limbs at three different frequencies). Sensory nerve 
dysfunction was defined as at least two abnormalities on any frequencies on the upper or 
lower limbs. 
Sensory nerve dysfunction was more prevalent among subjects with IGT compared to 
controls (58.3 vs. 10.3%, OR: 11.23, 95%CI: 3.57-35.35). This association was not influenced 
by BMI, systolic and diastolic blood pressure, heart rate and autonomic neuropathy (multiple 
adjusted OR: 13.87, 95%CI: 3.18-60.58), but further adjustment for glycaemic measures 
abolished the association (OR: 1.58, 95%CI: 0.07-35.68). Assessing the components of 
glycaemic measures separately, the association between sensory nerve dysfunction and IGT 
was not affected by HbA1c (OR: 13.94, 95%CI: 1.84-105.5). It was, however, substantially 
attenuated by fasting plasma glucose (OR: 6.75, 95%CI: 1.33-34.27) while the significance 
was lost after adjustment for 120-min postload glucose level (OR: 3.76, 95%CI: 0.26-54.10). 
In the pooled population assessed, independent determinants of sensory nerve dysfunction 
were older age, 120-min glucose, higher height and cardiovascular autonomic neuropathy at 
near significance.  
Conclusions: Sensory nerve dysfunction amongst subjects with IGT was not explained by 
cardiovascular covariates, only by glycaemic measures. In addition to 120-min glucose, 
cardiovascular autonomic neuropathy at borderline significance, age, and height were the 
independent determinants of sensory nerve dysfunction.  
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Introduction 
The clinical and prognostic importance of sensory nerve dysfunction has become evident in 
recent decades. Elucidating the potential risk factors for the development of nerve dysfunction 
is important, as it is already clear nowadays that even somatic nerve dysfunction should be 
considered as a significant risk factor for cardiovascular disease[1,2]. 
Over the past decade, impaired glucose tolerance (IGT) was frequently observed among 
subjects with idiopatic neuropathy [3-6]. However, this association could not be confirmed in 
one case-control study after adjustment for age and gender [7], and the role of IGT in the 
development of idiopathic neuropathy needs further investigation. Nonetheless, in population 
based studies, the prevalence of sensory nerve dysfunction was higher among people with 
IGT compared to healthy control subjects [8,9].  
Distal sensory neuropathy is considered the most important pathogenetic factor for the 
development of diabetic foot complications [10]. Whilst the role of traditional cardiovascular 
risk factors in the pathogenesis of diabetic neuropathy is well recognised [1,2,11-12], the 
relationship between cardiovascular risk factors and sensory nerve dysfunction in subjects 
with IGT is still unclear. We have previously reported that subjects with IGT and 
cardiovascular autonomic neuropathy have higher diastolic blood pressure and higher 
frequency of the non-dipping phenomenon compared to healthy controls [13].  
The present study was undertaken to (I) evaluate whether there is an association between IGT 
and sensory nerve dysfunction in a larger cohort than previously examined, and if this 
association exists, (II) to characterize the independent risk factors of sensory nerve 
dysfunction. 
 
Methods 
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Individuals diagnosed with isolated IGT in primary care during a screening program were 
referred to our department and recruited for the present study. Healthy volunteers working at 
our Department, as well as their relatives served as healthy controls. Those giving written 
informed consent underwent a 75g oral glucose tolerance test according to the WHO 
recommendation to confirm the diagnosis of isolated IGT (fasting blood glucose <6.0 mmol/l 
and 120 min value of 7.8–11.0 mmol/l) or normoglycaemia, respectively. Seventy-two people 
with isolated IGT and 39 healthy volunteers (HV) comparable for age and gender were 
assessed. Our study involved 33 men and 39 women with IGT (mean age: 58.72 years), and 
17 men and 22 women with normoglycaemia (mean age: 55.13 years). The study protocol 
was approved by the local ethics committee and all participants gave written informed 
consent.  
All subjects underwent a detailed neurological assessment to exclude subjects with carpal 
tunnel syndrome, and to detect symptoms and signs suggestive of neurological 
impairment. A general medical examination was performed with attention to distal muscle 
atrophy and skin changes. Sensory nerve function was assessed by the Neurometer R device 
(Baltimore, USA). Current perception threshold (CPT) was measured at median and peroneal 
nerves (digital branches) by the Neurometer device at three different frequencies (2 kHz, 250 
Hz, 5 Hz) assessing large myelinated, small myelinated, and small unmyelinated sensory 
nerve fibre function respectively [14-16]. The examiner was blinded to IGT status of the 
participants. Our main outcome measure, sensory nerve dysfunction was defined at least as 
two abnormal measures either on the upper or on the lower limb at any frequencies. The 
normal values for the three different frequency measurements of the peroneal and the median 
nerve were established by Evans et al [17].  
Body weight and height were measured in light clothing without shoes on a calibrated digital 
scale. Current smoking was defined as consuming ≥1 cigarette/day). Serum fasting and 120-
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min postload glucose as well as total cholesterol, HDL-cholesterol, LDL-cholesterol and 
triglyceride levels were measured on an AU 680 Beckman Chemistry System (Beckman 
Coulter Hungary Ltd., Budapest, Hungary), HbA1c with high-performance liquid 
chromatography (Bio-Rad Hungary Ltd., Budapest Hungary). 
Cardiovascular autonomic neuropathy was detected by standard cardiovascular reflex tests: 
heart rate responses to deep breathing, standing (30/15 ratio) and Valsalva maneouvre 
(Valsalva ratio) assessing mainly parasympathetic function, and blood pressure responses to 
standing and sustained handgrip assessing mainly sympathetic function. According to the 
Toronto Consensus Panel, blood pressure response to sustained handgrip is no longer 
regarded as an established clinical test but as an investigational test [18]. All reflex-tests were 
performed using Cardiosys H-01 12-lead portable ECG and non-invasive blood pressure 
monitoring system with analytical software developed by MDE Ltd., Hungary. The presence 
of autonomic neuropathy was defined as at least one abnormal cardiovascular reflex test 
[13,16,19]. 
24-hour blood pressure was evaluated by ambulatory blood pressure monitoring (ABPM, 
Meditech CardioTens-01) device [20]. Blood pressure was measured every 20 minutes during 
daytime and every 30 minutes during night-time. The mean values from the 24-hour 
recordings of systolic and diastolic blood pressure and heart rate parameters were used during 
the analysis. 
Participants were encouraged to avoid consuming caffeine and alcoholic beverages as well as 
tobacco products 12 hours preceding autonomic testing. They were asked to fast for 10 h 
overnight and to avoid heavy physical activity on the day before the examination. None of the 
participants were taking any drugs that could affect blood pressure or heart rate.  
 
Statistical methods 
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Data were expressed as mean±SD for normally distributed and median (interquartile range) 
for not normally distributed data (triglycerides, HDL-cholesterol, systolic blood pressure). 
The latter variables were log-transformed to adjust for skewness. For comparison between 
groups (IGT vs. control and subjects with vs. without sensory nerve dysfunction), either χ2-
test, 2 sample t-test or Mann-Whitney U test were used as required. 
The association between sensory nerve dysfunction and IGT was assessed using a logistic 
regression model with sensory nerve dysfunction as the dependent and IGT as the 
independent variable. To explore the potential explanatory variables, this model was further 
adjusted in a stepwise manner for groups of cardiovascular risk factors. As the final step of 
our analysis, we added individual glycemic variables, fasting and 120 min postprandial 
glucose values and HbA1c to models including all other cardiovascular risk factors. 
All variables univariately associated (p<0.1) with sensory nerve dysfunction were made 
available for a multiple logistic regression with stepwise backward elimination to determine 
independent risk factors for sensory nerve dysfunction. All analyses were performed using 
SPSS version 14.0, a two-side p-value <0.05 was considered as statistically significant. 
 
Results 
Baseline characteristics as well as the frequency of autonomic and sensory nerve dysfunction 
of participants with IGT and healthy volunteers are shown in Table 1. IGT subjects had 
significantly higher HbA1c, fasting plasma glucose concentrations, 120 min plasma glucose 
concentrations, weight, BMI, systolic and diastolic blood pressures and heart rate compared to 
controls. Both cardiovascular autonomic and sensory nerve dysfunction were significantly 
more prevalent among IGT subjects compared to the control group. The prevalence of sensory 
nerve dysfunction was 58.3% among subjects with IGT compared to 10% in the healthy 
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volunteers. Cardiovascular autonomic neuropathy was found in 42 IGT subjects (58.3%), 
while all healthy controls had normal autonomic function. 
Potential explanatory variables for the association between sensory nerve dysfunction and 
IGT are summarized in Table 2. The risk of sensory nerve dysfunction was eleven times 
higher among people with IGT compared to healthy controls (OR: 11.23, 95%CI: 3.57-35.35). 
This association was neither explained by BMI (OR after adjustment for BMI remained 12.97, 
95%CI: 3.65-46.00), nor by systolic and diastolic blood pressure and heart rate (OR after 
adjustment: 17.10, 95%CI: 4.28-68.28). Moreover, adjustment for autonomic neuropathy had 
no major effect on the OR (OR: 13.87, 95%CI: 3.18-60.58), while further adjustment for all 
glycaemic measures abolished the association (OR: 1.58, 95%CI: 0.07-35.68). When 
evaluating the glycaemic components separately, HbA1c had no major effect on the 
association between sensory nerve dysfunction and IGT (OR: 13.94, 95%CI: 1.84-105.5), 
while it was substantially attenuated by fasting plasma glucose (OR: 6.75, 95%CI: 1.33-
34.27). Significance of the association was lost when 120-min postload glucose level was 
added to the model (OR: 3.76, 95%CI: 0.26-54.10).  
Data of participants with and without sensory nerve dysfunction are presented in Table 3. 
Significant differences between those with and without sensory nerve dysfunction were 
detected for the following variables: age (p<0.003), gender (p<0.053), BMI (p<0.043), weight 
(p<0.001), height (p<0.033), HbA1c (p<0.0001), fasting plasma glucose (p<0.0001), 120 min 
plasma glucose (p<0.0001), cholesterol (p<0.031), LDL-cholesterol (p<0.027), cardiovascular 
autonomic neuropathy (p<0.0001), and IGT (p<0.0001). No differences were observed for 
smoking prevalence, triglyceride and HDL-cholesterol levels, systolic and diastolic blood 
pressure and heart rate.  
As 10% of healthy controls had also sensory nerve dysfunction, we have looked at the 
potential risk factors in the pooled population assessed hypothesis-generating analysis. The 
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presence of sensory nerve dysfunction was independently related to age, 120 min plasma 
glucose and height, and with cardiovascular autonomic neuropathy at borderline siginificance 
(Table 4). 
 
Discussion 
There are limited data on the prevalence of sensory nerve dysfunction in IGT. Some 
epidemiological studies have reported higher prevalence of neuropathy in people with IGT 
[8,9], while others could not confirm these results [21]. The association between IGT and 
sensory nerve dysfunction is not clear. While several uncontrolled observational studies have 
found an increased prevalence of IGT among individuals with idiopathic neuropathy [3,4-6], 
the only study using an appropriate control group was unable to demonstrate any association 
between IGT and idiopathic neuropathy after adjustment for age and gender. In this study 
patients with chronic idiopathic neuropathy had significantly higher serum triglyceride levels 
compared to controls [7]. In our study sensory nerve dysfunction was significantly more 
prevalent among people with IGT, while we couldn’t confirm any association with serum 
triglyceride levels. 
In some of the studies patients with painful sensory or idiopathic sensory neuropathy [6,7,22] 
were assessed. Importantly, all these patients had symptomatic neuropathy. However, this 
could be considered somewhat as the “tip of an iceberg”, as neuropathy in the majority of IGT 
patients is asymptomatic [9,23], as confirmed in our previous studies as well [13,16]. 
In our study, there was an eleven times higher odds ratio for sensory nerve dysfunction among 
people with IGT compared to healthy volunteers. Traditional cardiovascular risk factors did 
not explain this association. In the multiple logistic regression model, fasting glycaemia still 
had some effects on the association between sensory nerve dysfunction and IGT, but 120 min 
postload plasma glucose levels seem to be the major determinant of sensory impairment in 
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subjects with isolated IGT. Sensory nerve dysfunction was also present in 10% of healthy 
controls. Evaluating our pooled study population, including patients and controls,  age, 120 
min plasma glucose, height and cardiovascular autonomic neuropathy –although only at 
borderline significance- were independently related to sensory nerve dysfunction. 
The KORA F4 population-based study showed a relationship between 2-hour postload 
glucose and the presence of clinical distal sensory motor polyneuropathy in participants with 
combined impaired fasting glucose and IGT, as well as in those with known diabetes. No 
association were seen with fasting glucose and HbA
1c
 levels [23]. Our results confirm and 
also extend these findings, as we found that both fasting and 2-hour postload glucose levels 
were associated with the presence of sensory impairment. 
Cross-sectional studies have suggested that traditional cardiovascular risk factors may play a 
role in the pathogenesis of neuropathy in patients with diabetes mellitus [2,24,25]. Moreover, 
the EURODIAB Prospective Complication Study showed that apart from glyacemic control, 
the incidence of neuropathy was associated with higher triglyceride levels and body-mass 
index, smoking and hypertension [1]. Metabolic syndrome components seemed to be 
significantly associated with distal symmetrical polyneuropathy independent of glycemic 
status, although this effect was less pronounced than that of the presence of diabetes [26]. 
Obesity seemed to be an important mediator in the development of abnormal autonomic 
function and diminished diurnal indices in people with IGT [13]. In another study the 
presence of peripheral neuropathy and the severity of nerve dysfunction was independently 
associated with prediabetes, but not with metabolic syndrome [27]. Similarly, in our present 
study, 120 min plasma glucose level was independently associated with sensory nerve 
dysfunction, while obesity had no effect on the presence of sensory nerve dysfunction in our 
pooled population.Height is an independent risk factor for peripheral sensory neuropathy in 
patients with diabetes mellitus [28]. The adverse effect of height on nerve fibre function may 
11 
 
be attributed to the increasing length of nerve fibres as they lose their function distally with 
progression of diabetic polyneuropathy. A similar pathophysiological mechanism should be 
supposed in our population. 
Cardiovascular autonomic neuropathy has been documented to be associated with the 
presence of peripheral polyneuropathy [11,29]. Although at borderline siginificance 
cardiovascular autonomic neuropathy was independently related to sensory nerve dysfunction 
in our pooled population as well.  
In a cohort study of IGT subjects, baseline distal intraepidermal nerve fibre density (IENFD) 
was strongly related to fasting and 2-hour glucose during OGTT. After 1 year of lifestyle 
intervention of both fasting and postload glucose levels and proximal IENFD significant 
improvement was documented [30]. These observations suggest that, at least in the early 
stages, improvements in dysglycaemia could be helpful in ameliorating or even reversing 
nerve fibre damage in patients with IGT [30].  
The strength of our study is that subjects with isolated IGT have been recruited while 
autonomic neuropathy was included in the statistical analysis when searching the potential 
explanatory factors of sensory nerve dysfunction. In addition, 24-hour mean blood pressure 
values were assessed beside office blood pressure values.  
The relatively small sample size should be considered as weakness of the study. Further 
limitation is the definition of sensory nerve dysfunction as defined by two abnormal CPT 
parameters either on the upper or on the lower limb at any frequencies measured by the 
Neurometer. Indeed, it is not a widely used definition of sensory neuropathy. In the recent 
guideline, confirmed diagnosis of diabetic sensorimotor polyneuropathy was defined as any 
abnormality on nerve conduction (NC) studies and presence of symptom(s) or sign(s) of 
neuropathy. If no NC abnormality is present, a validated measure of small-fibre neuropathy 
(such as skin biopsy) had to be used [31]. However, the Toronto Consensus Panel [18,31] 
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refers to patients with diabetic neuropathy, while the aim of our study was to identify risk 
factors of sensory nerve dysfunction among IGT subjects. This way, we had to use a measure 
detecting early abnormalities rather than definite damage. The Neurometer device has been 
demonstrated as a sensitive, reproducible and, most importantly, a non-invasive method for 
the assessment of sensory nerve fibre function. It is able to detect functional abnormalities of 
all types of sensory nerve fibre [14,15,16]. The Neurometer has been used in studies in order 
to detect early subclinical sensory abnormalities among diabetic children and adolescents as 
well [32,33], thus in another group of patients having subclinical neural damage. Small-fibre 
damage is considered the earliest alteration in the course of diabetic neuropathy and is the 
most common feature of IGT associated neuropathy as well, and, according to our previous 
data, CPT 5 Hz frequency stimulation seems to be appropriate for the detection of small-fibre 
impairment in patients with IGT [16]. Finally, the Neurometer is able to distinguish between 
normoaesthesia, hypo- and hyperaesthesia, while the latter is considered as a feature of early 
sensory involvement.  
Due to the cross-sectional design of our study, we were unable to investigate the temporal 
relationship between sensory nerve dysunction and its determinants. 
In summary, our data do not support the role of traditional cardiovascular risk factors in the 
development of neural dysfunction among IGT subjects. Two-hour postprandial plasma 
glucose level might be the major determinant of early sensory impairment among IGT 
subjects. This observation might be also relevant to the development of risk reduction 
strategies. Cardiovascular autonomic neuropathy, age, 120 min plasma glucose and height 
were independent covariates of sensory nerve dysfunction in the pooled study population. 
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Table 1 Demographic data and clinical characteristics of participants with IGT and healthy 
volunteers. 
 
 Participants with IGT 
n꞊72 
Healthy Volunteers 
n꞊39 
p 
Age (years) 58.72±11.11 55.13±10.08 0.096 
Male# 33 (45.8) 17 (43.6) 0.844 
Smoking rate# 15 (21.1) 8 (20.5) 1.000 
Cardiovascular autonomic 
neuropathy# 
42 (58.3) 0 (0.0) <0.0001 
Sensory nerve dysfunction# 42 (58.3) 4 (10.3) <0.0001 
HbA
1c 
( %)  6.02±0.30 5.01±0.47 <0.0001 
HbA1c (mmol/mol) 42.30±3.29 31.29±5.11 <0.0001 
Height (cm) 167.59±8.52 169.86±9.10 0.196 
Weight (kg) 84.17±15.55 72.08±12.58 <0.0001 
BMI (kg/ m2 ) 29.91±4.72 24.97±3.99 <0.0001 
Fasting plasma glucose 
(mmol/l) 
5.63±0.59 4.68±0.48 <0.0001 
120 min plasma glucose 
(mmol/l) 
8.76±0.97 4.95±0.44 <0.0001 
Cholesterol (mmol/l)  
 
5.04±1.09 5.03±0.97 0.957 
Triglyceride (mmol/l) 
 
1.30 [0.99; 1.67] 1.30 [1.02; 1.80] 0.476 
LDL-cholesterol (mmol/l)  
 
3.13±0.88 3.10±0.91 0.912 
HDL-cholesterol (mmol/l) 
 
1.33 [1.16; 1.62] 1.28 [0.98; 1.70] 0.849 
Systolic blood pressure 
(mmHg) 
124 [118; 131] 120 [106; 124] <0.0001 
Diastolic blood pressure 
(mmHg) 
75.23±6.82 70.95±6.04 0.002 
Heart rate (/min) 72.72±9.77 77.61±8.73 0.011 
 
Data are reported as mean±SD or median [IQR]. Between group differences are reported 
according to 2-sample t-tests or Mann-Whitney U-tests and χ2-tests as indicated. 
 
# Categorical variables are reported as n (%) 
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Table 2 Potential explanatory variables of the association between sensory nerve dysfunction 
and impaired glucose tolerance. 
 
 
Odds Ratio 95% CIs p 
Model 1 ꞊ IGT 11.23 3.57-35.35 <0.0001 
Model 2 ꞊ Model 1 + BMI 12.97 3.65-46.00 <0.0001 
Model 3 ꞊ Model 2 + 
RRS;RRD;HR 
17.10 4.28-68.28 <0.0001 
Model 4 ꞊ Model 3 + 
Autonomic neuropathy 
13.87 3.18-60.58 <0.0001 
Model 5 ꞊ Model4 + 
HbA1c; Fasting plasma 
glucose; 120 min plasma 
glucose 
1.58 0.07-35.68 0.77 
Model 6 ꞊ Model 4 + 
HbA1c 
13.94 1.84-105.50 <0.0001 
Model 7 ꞊ Model 4 + 
Fasting plasma glucose 
6.75 1.33-34.27 0.021 
Model 8 ꞊ Model 4 + 120 
min plasma glucose 
3.76 0.26-54.10 0.33 
 
Logistic regression with sensory nerve dysfunction as outcome 
RRS: 24-hour systolic blood pressure mean, RRD: 24-hour diastolic blood pressure mean 
HR: 24-hour mean heart rate 
 
 
21 
 
Table 3 Demographic data and clinical characteristics in participants with and without 
sensory nerve dysfunction 
 Participants without 
sensory nerve 
dysfunction 
n꞊65 
Participants with 
sensory nerve 
dysfunction 
n꞊46 
p 
Age (years) 54.95±10.39 61.00±10.61 0.003 
Male# 24 (36.9%) 26 (56.5%) 0.053 
Smoking rate# 15 (23.4%) 8 (17.4%) 0.485 
Cardiovascular autonomic 
neuropathy# 
16 (24.6%) 26 (56.5%) 0.001 
Impaired glucose tolerance# 30 (46.2%) 42 (91.3%) <0.0001 
HbA
1c 
( %)  5.47±0.67 5.91±0.38 <0.0001 
HbA1c (mmol/mol) 36.23±7.32 41.14±4.24 <0.0001 
Height (cm) 166.90±8.96 170.50±8.00 0.033 
Weight (kg) 76.10±15.40 85.62±14.36 0.001 
BMI (kg/ m2 ) 27.36±5.34 29.33±4.41 0.043 
Fasting plasma glucose 
(mmol/l) 
5.05±0.71 5.63±0,58 <0.0001 
120 min plasma glucose 
(mmol/l) 
6.70±2.02 8.44±1.50 <0.0001 
Cholesterol (mmol/l)  
 
5.20±1.12 4.78±0.90 0.031 
Triglyceride (mmol/l)  
 
1.30 [0.93; 1.70] 1.30 [1.00; 1.70] 0.793 
LDL-cholesterol (mmol/l)  
 
3.29±0.96 2.88±0.72 0.027 
HDL-cholesterol (mmol/l)  
 
1.35 [1.10; 1.62] 1.31 [1.15; 1.38] 0.573 
Systolic blood pressure 
(mmHg) 
122 [116; 129]  121 [116; 130] 0.398 
Diastolic blood pressure 
(mmHg) 
72.86±6.17 74.98±7.61 0.112 
Heart rate (/min) 75.22±9.15 73.29±10.35 0.307 
 
Data are reported as mean±SD or median [IQR]. Between group differences are reported 
according to 2-sample t-tests or Mann-Whitney U-tests and χ2-tests as indicated. 
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Table 4 Independent determinants of sensory nerve dysfunction in the pooled population 
based on logistic regression with stepwise elimination. Other variables available for the model 
(p<0,1) from Table 3 
 
 Odds Ratio 95% CIs p 
Cardiovascular 
autonomic 
neuropathy 
3.28 0.99-
10.90 
0.052 
Age (1/years) 1.06 1.00-1.12 0.037 
120 min plasma 
glucose (1/mmol/l) 
1.78 1.20-2.63 0.004 
Height (1/cm) 1.12 1.04-1.21 0.004 
 
 
 
